ReviewClinical microbiology reviews2017
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.
Review in Clinical microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 655 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
655 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,134 citations in OpenAlex.
- Prosthetic Valve Endocarditis byPathogens (Basel, Switzerland) · 2026Pooled it
- Global Epidemiology and Antimicrobial Resistance of Metallo-β-Lactamase (MBL)-Producing Acinetobacter Clinical Isolates: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Unveiling the role of adhesin proteins in controllingInfection and immunity · 2025Pooled it
- Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data.Antimicrobial agents and chemotherapy · 2025Trial
- Loss of CsrA inProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Structural insights and therapeutic targets in Acinetobacter baumannii capsule biosynthesis.FEBS letters · 2026Article
- Antibacterial efficacy of Nonea lutea-mediated silver and gold nanoparticles against multidrug-resistant clinical pathogens harboring virulence and resistance genes.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- ISmLife · 2026Article
- Complete genome sequence ofMicrobiology resource announcements · 2026Article
- Evaluation of cefiderocol trailing and other unclear susceptibility testing endpoints forJournal of clinical microbiology · 2026Article
- A Rare Case of Community-Acquired Acinetobacter Urethritis in an Immunocompetent Adult Woman.Cureus · 2026Article
- Development of Loop-Mediated Isothermal Amplification with a Lateral Flow Dipstick for Detection of theInternational journal of molecular sciences · 2026Article
- Antibacterial and Immunomodulatory Effects ofInternational journal of molecular sciences · 2026Article
- Review
- The VgrG2 effector of Acinetobacter baumannii mediates immune evasion by repressing Csu pilus assembly and triggering phagocyte methuosis.Nature communications · 2026Article
- Molecular characterization and genotypic diversity of extensively drug-resistant Acinetobacter baumannii from endotracheal aspirates in a pediatric intensive care unit in Sulaimani, Iraq.Molecular biology reports · 2026Article
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Acinetobacter baumannii lipooligosaccharide core region promotes CD14-dependent TLR4 endocytosis and enhances pathogenicity through interferon-β production.PLoS pathogens · 2026Article
- In silico metabolic profiling of non-baumannii Acinetobacter species uncovers conserved functions and provides first evidence of siderophore biosynthetic genes in Acinetobacter junii.Scientific reports · 2026Article
- Mobilization of the AbGRI4 resistance island inMicrobiology spectrum · 2026Article
595 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Acinetobacter is a complex genus, and historically, there has been confusion about the existence of multiple species. The species commonly cause nosocomial infections, predominantly aspiration pneumonia and catheter-associated bacteremia, but can also cause soft tissue and urinary tract infections. Community-acquired infections by Acinetobacter spp. are increasingly reported. Transmission of Acinetobacter and subsequent disease is facilitated by the organism's environmental tenacity, resistance to desiccation, and evasion of host immunity. The virulence properties demonstrated by Acinetobacter spp. primarily stem from evasion of rapid clearance by the innate immune system, effectively enabling high bacterial density that triggers lipopolysaccharide (LPS)-Toll-like receptor 4 (TLR4)-mediated sepsis. Capsular polysaccharide is a critical virulence factor that enables immune evasion, while LPS triggers septic shock. However, the primary driver of clinical outcome is antibiotic resistance. Administration of initially effective therapy is key to improving survival, reducing 30-day mortality threefold. Regrettably, due to the high frequency of this organism having an extreme drug resistance (XDR) phenotype, early initiation of effective therapy is a major clinical challenge. Given its high rate of antibiotic resistance and abysmal outcomes (up to 70% mortality rate from infections caused by XDR strains in some case series), new preventative and therapeutic options for Acinetobacter spp. are desperately needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.